Biocardia Net Worth
Biocardia Net Worth Breakdown | BCDA |
Biocardia Net Worth Analysis
Biocardia's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Biocardia's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Biocardia's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Biocardia's net worth analysis. One common approach is to calculate Biocardia's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Biocardia's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Biocardia's net worth. This approach calculates the present value of Biocardia's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Biocardia's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Biocardia's net worth. This involves comparing Biocardia's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Biocardia's net worth relative to its peers.
Enterprise Value |
|
To determine if Biocardia is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biocardia's net worth research are outlined below:
| Biocardia had very high historical volatility over the last 90 days | |
| Biocardia has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 477 K. Net Loss for the year was (11.57 M) with loss before overhead, payroll, taxes, and interest of (7.48 M). | |
| Biocardia currently holds about 8.61 M in cash with (9.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49. | |
| Roughly 14.0% of the company shares are held by company insiders | |
| Latest headline from investing.com: Biocardia CEO Peter Altman acquires 2,524 in common stock |
Biocardia Quarterly Good Will |
|
Biocardia uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biocardia. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biocardia's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Biocardia's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biocardia is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biocardia backward and forwards among themselves. Biocardia's institutional investor refers to the entity that pools money to purchase Biocardia's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wells Fargo & Co | 2024-06-30 | 0.0 | Octavia Wealth Advisors, Llc | 2024-06-30 | 0.0 | Commonwealth Equity Services Inc | 2024-06-30 | 0.0 | Northern Trust Corp | 2024-06-30 | 0.0 | Simplex Trading, Llc | 2024-06-30 | 0.0 | Wedbush Morgan Securities Inc | 2024-06-30 | 0.0 | Brown Advisory Holdings Inc | 2024-06-30 | 0.0 | Family Management Corporation | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 0.0 | Susquehanna International Group, Llp | 2024-06-30 | 44.6 K | Geode Capital Management, Llc | 2024-06-30 | 13 K |
Follow Biocardia's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.79 M.Market Cap |
|
Project Biocardia's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.87) | (3.68) | |
| Return On Capital Employed | 18.75 | 19.69 | |
| Return On Assets | (3.87) | (3.68) | |
| Return On Equity | 7.22 | 7.58 |
When accessing Biocardia's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Biocardia's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biocardia's profitability and make more informed investment decisions.
Please note, the presentation of Biocardia's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biocardia's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biocardia's management manipulating its earnings.
Evaluate Biocardia's management efficiency
Biocardia has return on total asset (ROA) of (1.1593) % which means that it has lost $1.1593 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.0362) %, meaning that it created substantial loss on money invested by shareholders. Biocardia's management efficiency ratios could be used to measure how well Biocardia manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biocardia's Return On Capital Employed is projected to increase based on the last few years of reporting. The current year's Return On Equity is expected to grow to 7.58, whereas Return On Tangible Assets are projected to grow to (3.68). At present, Biocardia's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 265.9 K, whereas Total Assets are forecasted to decline to about 2.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.14) | (1.08) | |
| Tangible Book Value Per Share | (1.14) | (1.08) | |
| Enterprise Value Over EBITDA | (1.23) | (1.30) | |
| Price Book Value Ratio | (8.77) | (9.21) | |
| Enterprise Value Multiple | (1.23) | (1.30) | |
| Price Fair Value | (8.77) | (9.21) | |
| Enterprise Value | 14.3 M | 13.6 M |
Management at Biocardia focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 83.1331 | Revenue 428 K | Quarterly Revenue Growth (0.93) | Revenue Per Share 0.264 | Return On Equity (7.04) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biocardia insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biocardia's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biocardia insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Biocardia Corporate Filings
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 13th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 28th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 6th of September 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Biocardia Earnings per Share Projection vs Actual
Biocardia Corporate Management
| Edward Gillis | Senior Devices | Profile | |
| Ian McNiece | Chief Officer | Profile | |
| Sujith Shetty | Chief Regulatory | Profile | |
| Sujith MBBS | Chief Regulatory | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.03) | Revenue Per Share 0.264 | Quarterly Revenue Growth (0.93) | Return On Assets (1.16) | Return On Equity (7.04) |
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biocardia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.